Watson Launches Authorized Oxandrin Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch follows denial of Savient’s motion for preliminary injunction to prevent Sandoz and Upsher-Smith from launching generic oral anabolic agent.
You may also be interested in...
Savient Shifts Focus To Puricase Submission For Refractory Gout
The firm restructures its commercial operations and terminates 19-rep sales force detailing its anabolic agent Oxandrin.
Savient Shifts Focus To Puricase Submission For Refractory Gout
The firm restructures its commercial operations and terminates 19-rep sales force detailing its anabolic agent Oxandrin.
Schering-Plough's Clarinex and Savient's Oxandrin Challenged By Paragraph IV Certifications
Schering-Plough's antihistamine franchise is facing Paragraph IV challenges. An ANDA for Clarinex(desloratadine) 5 mg tablets, as well as 2.5 mg and 5 mg orally disintegrating tablets, was filed on June 21. An ANDA was also filed for Clarinex-D 24 Hour extended release 5 mg/240 mg tablets. Clarinex 5 mg tablets and the orally disintegrating formulations are protected with a patent through Jan.7, 2020, including a pediatric extension, while patent protection for the extended release 5 mg/240 mg version runs through March 28, 2022, according to the "Orange Book." ANDAs with Paragraph IV certifications have also been filed for Savient's oral anabolic agent Oxandrin(oxandrolone) tablets 2.5 mg and 10 mg tablets. Both formulations are protected by patents through Dec. 5, 2015